A5032718078- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Glioma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Head and Neck Cancer Studies
- Thyroid Cancer Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Lung Cancer Research Studies
- Immunodeficiency and Autoimmune Disorders
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Immune Cell Function and Interaction
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
- Eosinophilic Disorders and Syndromes
National Cancer Institute
2016-2025
Center for Cancer Research
2015-2024
National Institutes of Health
2015-2024
Cancer Institute (WIA)
2022-2024
National Cancer Institute
2023
University of Pennsylvania
2020
Yale University
2019
Medical College of Wisconsin
2019
Oregon Health & Science University
2016
Instituto Nacional de Enfermedades Neoplásicas
2016
A deletion variant of epidermal growth factor receptor (EGFRvIII) is a known driver mutation in subset primary and secondary glioblastoma multiforme. Adoptive transfer genetically modified chimeric antigen (CAR) lymphocytes has demonstrated efficacy hematologic malignancies but still early development for solid cancers. The surface expression the truncated extracellular ligand domain created by EGFRvIII makes it an attractive target CAR-based cancer treatment. Patients with recurrent...
We conducted a basket clinical trial to assess the feasibility of such design strategy and independently evaluate effects multiple targeted agents against specific molecular aberrations in histologic subtypes concurrently.We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell cancer, thymic malignancies who underwent genomic characterization oncogenic drivers. Patients were onto not-otherwise-specified arm treated standard-of-care therapies or one following five...
Erdheim-Chester Disease (ECD) is a rare, potentially fatal, multi-organ myeloid neoplasm occurring mainly in adults. The diagnosis established by clinical, radiologic, and histologic findings; ECD tumors contain foamy macrophages that are CD68+, CD163+, CD1a-, frequently S100-. purpose of this report to describe the clinical molecular variability ECD. Sixty consecutive patients (45 males, 15 females) were prospectively evaluated at NIH Clinical Center between 2011 2015. Comprehensive imaging...
Abstract Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing 68 HSTLs, we define recurrently mutated driver genes copy-number alterations in disease. Chromatin-modifying genes, including SETD2, INO80, ARID1B, were commonly HSTL, affecting 62% cases. HSTLs manifest frequent mutations STAT5B (31%), STAT3 (9%), PIK3CD for which there currently exist potential targeted therapies. In addition, noted...
Clonal evolution of osimertinib-resistance mechanisms in EGFR mutant lung adenocarcinoma is poorly understood. Using multi-region whole-exome and RNA sequencing prospectively collected pre- post-osimertinib-resistant tumors, including at rapid autopsies, we identify a likely mechanism driving osimertinib resistance all patients analyzed. The majority acquire two or more either concurrently temporal sequence. Focal copy-number amplifications occur subclonally are spatially temporally...
Histiocytic and interdigitating dendritic cell sarcomas are rare tumors originating from bone marrow-derived myeloid stem cells. Recent studies have shown evidence of cross-lineage transdifferentiation B cells in follicular lymphoma to histiocytic sarcomas. In this study, we report the morphologic, molecular cytogenetic analysis seven cases chronic lymphocytic leukemia/small (CLL/SLL) associated with All patients were elderly males (median age 71 years). The B-cell neoplasms preceded...
Follicular lymphoma (FL), a common in adults, occurs rarely pediatric and young adult patients. Most cases have been described as grade 3, but the criteria to distinguish variant of FL (PFL) from usual (UFL) seen adults are not well defined. We undertook study patients under age 30. identified 63 cases, which were analyzed by morphology, immunohistochemistry, polymerase chain reaction analysis IGH@ IGK@ clonality. These data correlated with clinical findings including stage, treatment,...
Significance Survival from malignant mesothelioma, particularly pleural is very poor. For patients with some cancers, overall survival following platinum chemotherapy better for germline mutations in DNA repair and related genes than without such mutations. We evaluated this relationship mesothelioma. Following chemotherapy, was significantly longer loss-of-function BAP1 compared no The effect of genotype highly significant but not peritoneal remained after adjusting gender age at diagnosis....
Peripheral T-cell lymphomas (PTCLs) are functionally and morphologically complex. Epstein-Barr virus (EBV)-positive B cells have been reported in angioimmunoblastic lymphoma (AITL) other PTCLs may mimic Hodgkin/Reed-Sternberg (HRS) cells, but EBV-negative HRS-like not described. We wished to assess the nature of PTCL associated with determine whether be seen. identified 57 cases as containing cells. These included 32 AITL, 19 PTCL, otherwise specified (NOS), 3 PTCL-NOS, follicular variant, 1...
Abstract Purpose: Adoptive transfer of activated autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in patients with metastatic melanoma. Responding generally do not have significant changes noncutaneous RECIST targets before 30 to 60 days following TIL infusion, and complete responses are often confirmed for 1 2 years. There is a critical need biomarker that provide early information regarding the likelihood duration response enable rational decisions...
KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective MEK kinase inhibitor the Ras/Raf/MEK/ERK pathway.Advanced nonsmall-cell lung cancer (NSCLC) patients failing one two prior regimens underwent profiling. wild-type were randomized erlotinib (150 mg daily) or combination selumetinib (100 daily). mutant (75 b.i.d.) combination. The primary end points progression-free survival...